WP
ELEV

Woodline Partners’s Elevation Oncology ELEV Stock Holding History

Woodline Partners’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24,365
Closed -$190K – 727
2021
Q3 		$190K Sell
24,365
-88,066
-78% -$952K ﹤0.01% 577
2021
Q2 		$1.53M Buy
+112,431
New +$1.39M 0.03% 385

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Woodline Partners's ELEV Position: Q4 2021 in Review

Woodline Partners sold out of Elevation Oncology (ELEV) in Q4 2021, closing a stake of 24,365 shares — an estimated $190K sold.

Woodline Partners first reported a position in ELEV in Q2 2021 and held it in 2 quarters. The position peaked at $1.53M in Q2 2021. 35 funds tracked by Wall St. Rank hold ELEV as of Q4 2021.

  • Woodline Partners reported no remaining Elevation Oncology position as of Q4 2021 after selling out during the quarter.
  • Woodline Partners sold 24,365 Elevation Oncology shares in Q4 2021, an estimated $190K.
  • Woodline Partners first reported a position in Elevation Oncology in Q2 2021 and held it in 2 quarters.
  • Woodline Partners's Elevation Oncology position peaked at $1.53M in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2021.

Based on Woodline Partners's 13F filing for Q4 2021, filed 14 Feb 2022.